(2-Acetyloxy-3-octadec-9-enoxypropyl) acetate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: (2-Acetyloxy-3-octadec-9-enoxypropyl) acetate
• 化学式: C₂₅H₄₆O₅
• 分子量: 426.6
• InChiKey: OHDKWRQTPPAVRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  30
• 可旋转键数：
  23
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Methods, compositions and elements for the determination of lipase
  申请人：EASTMAN KODAK COMPANY (a New Jersey corporation)

  公开号：EP0101046A1

  公开（公告）日：1984-02-22

  The present disclosure relates to methods, compositions and elements for the determination of the amount of lipase in a sample. The method comprises the steps of: (a) contacting the sample with a reagent composition comprising: i) a lipase substrate which is a glycerol triester oil having in one of its two a-ester positions a long chain alkyl group having at least 8 carbon atoms and, in its two remaining ester positions, short chain alkyl groups such that, if the long chain alkyl group is hydrolyzed, the resulting diester is water soluble; and ii) an esterase enzyme capable of catalyzing the hydrolysis of a water soluble glycerol diester to glycerol; and (b) detecting the rate at which glycerol is formed. The compositions of the present invention include the substrate and enzyme as defined. The element of the invention comprises a support having thereon the described composition. The invention is useful for determining lipase in samples which contain endogenous glycerol, such as blood serum and other body fluids.

  本公开涉及测定样品中脂肪酶含量的方法、组合物和元件。该方法包括以下步骤 (a) 将样品与试剂组合物接触，试剂组合物包括 i) 一种脂肪酶底物，它是一种甘油三酯油，在其两个 a 酯位中的一个酯位上具有至少 8 个碳原子的长链烷基，而在其剩余的 两个酯位上具有短链烷基，因此，如果长链烷基被水解，则生成的二酯 是水溶性的；以及 能够催化水溶性甘油二酯水解为甘油的酯酶；以及 (b) 检测甘油形成的速率。 本发明的组合物包括所定义的底物和酶。本发明的元件包括一个支架，其上有所述的组合物。本发明适用于测定含有内源性甘油的样品，如血清和其他体液中的脂肪酶。
• Intravascular stent with cytoskeletal inhibitors for the prevention of restenosis
  申请人：Boston Scientific Limited

  公开号：EP1512398A1

  公开（公告）日：2005-03-09

  Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

  提供了抑制哺乳动物宿主血管创伤后狭窄或再狭窄的方法，包括向宿主施用治疗有效剂量的细胞抑制剂和/或细胞骨架抑制剂，以便对创伤血管进行生物支架治疗。还提供了一种抑制或减少血管创伤后血管重塑的方法，包括施用有效量的细胞骨架抑制剂。还提供了包含本发明治疗剂的药物组合物和试剂盒。
• Use of cytoskeletal inhibitors in crystalline form for the inhibition or prevention of restenosis
  申请人：BOSTON SCIENTIFIC SCIMED LIMITED

  公开号：EP2098230A1

  公开（公告）日：2009-09-09

  Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

  提供了抑制哺乳动物宿主血管创伤后狭窄或再狭窄的方法，包括向宿主施用治疗有效剂量的细胞抑制剂和/或细胞骨架抑制剂，以便对创伤血管进行生物支架治疗。还提供了一种抑制或减少血管创伤后血管重塑的方法，包括施用有效量的细胞骨架抑制剂。还提供了包含本发明治疗剂的药物组合物和试剂盒。
• Dosage form comprising taxol in crystalline form
  申请人：BOSTON SCIENTIFIC SCIMED LIMITED

  公开号：EP2292225A1

  公开（公告）日：2011-03-09

  Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

  提供了抑制哺乳动物宿主血管创伤后狭窄或再狭窄的方法，包括向宿主施用治疗有效剂量的细胞抑制剂和/或细胞骨架抑制剂，以便对创伤血管进行生物支架治疗。还提供了一种抑制或减少血管创伤后血管重塑的方法，包括施用有效量的细胞骨架抑制剂。还提供了包含本发明治疗剂的药物组合物和试剂盒。
• Delivery of a bioactive material
  申请人：——

  公开号：US20040176328A1

  公开（公告）日：2004-09-09

  A solid phannaceutical composition comprising a water-soluble bioactive material and an encapsulating material which is present in the composition in the form of continuous solid phase, and in which solid particles of the bioactive material are dispersed and encapsulated in the continuous solid phase of the encapsulating material, wherein each of the bioactive material and the encapsulating material is normally a solid at room temperature and the melting point of the encapsulating material is lower than the melting point of the bioactive material, the bioactive material being preferably a bisphosphonate, most preferably alendronate, and the encapsulating material includes an enhancer, preferably a mono- or di-glyceride, or an encapsulating surfactant, preferably, a polyoxyethylene/polyoxypropylene block copolymer having surface active properties, and a process for preparing the composition in which solid particles of the bioactive material are mixed with and dispersed in the encapsulating material which is in molten (liquid) form; and cooling the molten form of the encapsulating material to form a solid pharmaceutical composition having the solid particles of the bioactive material dispersed and encapsulated in a continuous solid phase of the encapsulating material.

  一种固体药物组合物，包括水溶性生物活性材料和封装材料，封装材料以连续固相的形式存在于组合物中，其中生物活性材料的固体颗粒分散并封装在封装材料的连续固相中，其中生物活性材料和封装材料在室温下通常都是固体，封装材料的熔点低于生物活性材料的熔点、生物活性材料最好是双膦酸盐，最好是阿仑膦酸盐，包封材料包括增强剂，最好是单甘油酯或双甘油酯，或包封表面活性剂，最好是具有表面活性的聚氧乙烯/聚氧丙烯嵌段共聚物，以及制备该组合物的工艺，其中生物活性材料的固体颗粒与处于熔融（液体）状态的包封材料混合并分散在包封材料中；冷却封装材料的熔融状态，形成固体药物组合物，其中生物活性材料的固体颗粒分散并封装在封装材料的连续固相中。